RegenxBio Inc - Company Profile
Powered by 
All the data and insights you need on RegenxBio Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date RegenxBio Inc Strategy Report
- Understand RegenxBio Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
RegenxBio Inc (RegenxBio), formerly ReGenX Biosciences LLC, is a clinical-stage biotechnology company involved in the discovery and development of gene therapy. It is focused on the treatment of various retinal, metabolic, and neurodegenerative diseases. The company develops, commercializes, and licenses recombinant adeno-associated virus (AAV) gene therapy. RegenxBio's products include AAV plasmids, AAV vector reporter systems, and custom AAV vectors. The company’s gene therapy product candidates deliver genes to cells to address genetic defects and enable cells in the body to produce therapeutic proteins or antibodies that act on the disease. RegenxBio employs its proprietary NAV technology platform, a gene delivery technology, to advance its product candidates. RegenxBio is headquartered in Rockville, Maryland, the US.
Headquarters
United States of America
Address
9804 Medical Center Drive, Rockville, Maryland, 20850
Website
regenxbio.com
Telephone
1 240 5528181
No of Employees
344
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RGNX (NASD)
Revenue (2022)
$90.2M
-19.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
6%
(2022 vs 2021)
Market Cap*
$858.3M
Net Profit Margin (2022)
XYZ
-17.4%
(2022 vs 2021)
* As of and is in US$
RegenxBio Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Pipeline | Regenexbio |
| RGX-111: Mucopolysaccharidosis Type I | NAV |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In May, the company announced that its NAV technology platform will support Bespoke Gene Therapy Consortium's first rare disease clinical portfolio. |
| 2022 | Others | In December, the company announced a comprehensive program update to outline its progress and development plans for RGX-181 and RGX-381. |
| 2022 | Contracts/Agreements | In December, the company entered into an ATM Equity OfferingSM sales agreement with BofA Securities for the shares of its common stock. |
Competitor Comparison
| Key Parameters | RegenxBio Inc | F. Hoffmann-La Roche Ltd | Sanofi | Novartis AG | BioMarin Pharmaceutical Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | France | Switzerland | United States of America |
| City | Rockville | Basel | Paris | Basel | Novato |
| State/Province | Maryland | - | Ile-de-France | - | California |
| No. of Employees | 344 | 103,605 | 87,994 | 76,057 | 3,401 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Allan M. Fox | Chairman | Executive Board | 2020 | 76 |
| Kenneth T. Mills | Director; President; Chief Executive Officer | Executive Board | 2009 | 49 |
| Vittal K. Vasista | Chief Financial Officer | Senior Management | 2009 | 56 |
| Curran M. Simpson | Chief Operating Officer | Senior Management | 2023 | 62 |
| Patrick J. Christmas II | Chief Legal Officer | Senior Management | - | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward